Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06792708 · ClinicalTrials.gov registry record
Observational Study of LUMRYZ in Narcolepsy
A clinical trial of Narcolepsy, sponsored by Avadel.
- Completed
- Registry status
- 71
- Enrollment target
- 12
- Study locations
NCT06792708: Completed study of Narcolepsy, sponsored by Avadel.
NCT06792708 is a study of Narcolepsy that has completed, run by Avadel. The registered enrollment target is 71 participants, below the 375-participant average among 12 other Narcolepsy trials with a reported enrollment target (81% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06792708, a study of Narcolepsy, has completed, sponsored by Avadel.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is an observational study of LUMRYZ prescribed in clinical practice. Patients are asked if they would be willing to complete questionnaires over a 4-month period after starting LUMRYZ. The questionnaires ask about narcolepsy symptoms, experience with LUMRYZ, and quality of life.
Primary Outcome
Change from the first visit (baseline), prior to start of LUMRYZ, to Month 4; measure of sleepiness with total possible score of 0-24 (higher score equivalent to higher sleepiness)
Conditions Studied
Interventions
- DRUG LUMRYZ
Study Locations (12)
Pennsylvania
- Abington Neurological Associates - Abington
- Pulmonology Associates, Inc. - Wynnewood
- Respiratory Specialists - Wyomissing
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- Ohio Sleep Medicine Institute - Dublin
Texas
- Tricoastal Narcolepsy and Sleep Disorder Center - Sugar Land
- Northwest Houston Neurology - Tomball
Florida
- Jeremy D McConnell, MD PA - Bradenton
Michigan
- Comprehensive Sleep Center - East Lansing
New Jersey
- Patient First MD - Middletown
New York
- Ghaly Sleep Management Services - East Syracuse
South Carolina
- Bogan Sleep Consultants - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2024-07-18 |
| Est. Completion | 2025-10-28 |
What the finished NCT06792708 record still lists
NCT06792708 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 375-participant average among 12 other Narcolepsy trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Narcolepsy appearing as the primary indexed condition, and to 1 intervention - of which LUMRYZ is the first listed.
NCT06792708 lists 12 locations in 8 states (Pennsylvania, Ohio, Texas).
Frequently Asked Questions
What is clinical trial NCT06792708 about?
NCT06792708 is a clinical study titled "Observational Study of LUMRYZ in Narcolepsy". This is an observational study of LUMRYZ prescribed in clinical practice. Patients are asked if they would be willing to complete questionnaires over a 4-month period after starting LUMRYZ. The questionnaires ask about narcolepsy symptoms, experience with LUMRYZ, and quality of life.
What is the current status of trial NCT06792708?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2024-07-18. Estimated completion is 2025-10-28.
What conditions does trial NCT06792708 study?
This clinical trial studies the following conditions: Narcolepsy.
What interventions are being tested in trial NCT06792708?
The interventions under investigation include: LUMRYZ (DRUG).
Who is sponsoring clinical trial NCT06792708?
This trial is sponsored by Avadel, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06792708 being conducted?
This trial has 12 study locations across Florida, Michigan, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Narcolepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06792708's enrollment target sits among peer trials
71 9th of 12 higher than 4 of 12 other Narcolepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Narcolepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SUNOSI® (Solriamfetol) Pregnancy Registry
RECRUITING
-
A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
RECRUITING · Phase 1
-
Child and Adolescent Registry for Participants With Narcolepsy
RECRUITING
-
WAKIX® (Pitolisant) Pregnancy Registry
RECRUITING
-
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy
COMPLETED · Phase 2
-
Narcolepsy Nightmare Study
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI